ASTH

ASTH (Astrana Health, Inc.) Analyst Note Date: 2026-06-13 Current Price: $39.17

1. Structural Readiness

State: Context-only Conservative Entry: — (Awaiting confirmed breakout) Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone) Current Price: $39.17 Extension: — ATR Current: 3.8% (Productive / Within historical sweet spot of 4–6% range, indicating healthy volatility for position sizing)

2. Thesis Layer

Thesis Status: TACTICAL / Setup-Led Secular Exposure: None named at this date.

There is no named macro or secular thesis attached to this specific setup as of 2026-06-13. This is a tactical, setup-led name. The conviction must be derived strictly from the quality of the structural setup (the forming coil) and the underlying business fundamentals, rather than a broader thematic tailwind. We do not invent a thesis; we judge the name on its ability to execute its current business model and the technical readiness of the price structure.

3. The Business

Company Overview: Astrana Health, Inc. is a physician-centric, technology-enabled healthcare management company. It operates an integrated healthcare delivery platform that empowers providers to participate in value-based care arrangements. The company delivers medical services throughout the United States, primarily serving patients covered by private insurance, Medicare, Medicaid, and HMOs, with a small portion of revenue from non-insured patients.

Business Model & Segments: The company operates through three reportable segments:

• Care Partners: Revenue from care coordination and management services.
• Care Delivery: Revenue from direct medical services.
• Care Enablement: Revenue from technology and data solutions.

Key Operational Metrics (as of Q1 2026 / FY2026 Outlook):

• Revenue Growth: In Q1 2026, Astrana delivered revenue of $965.1 million, up 56% year-over-year.
• Profitability: Adjusted EBITDA for Q1 2026 was $66.3 million, up 82% year-over-year.
• Member Base: The company serves approximately 1.55 million members in value-based care arrangements.
• Risk Arrangements: Approximately 80% of care partners' revenue and 40% of owned membership are in full risk arrangements.
• Platform Efficiency: Providers actively using the platform achieve a 24% higher gap closure rate and a 30% higher annual wellness visit completion rate.
• Acquisition Integration: The company completed the acquisition of Prospect Medical Group and Prospect Medical Systems on July 1, 2025, for a purchase price of $674.9 million. This acquisition has been integrated into the Q1 2026 results.
• Cost Discipline: The 2026 plan assumes a blended cost trend of approximately 5.2%. Q1 actuals were consistent or better than planned across all lines of business.

Management Expectations (Recorded as of 2026-05-07): Management reaffirmed the full-year 2026 outlook:

• Total Revenue: Expected between $3.8 billion and $4.1 billion.
• Adjusted EBITDA: Expected between $250 million and $280 million.
• Free Cash Flow: Expected between $105 million and $132.5 million.

4. Archetype and Conviction

Archetype: Growth Leader / Margin Inflector The company fits the archetype of a Growth Leader with Margin Inflector characteristics. The 56% revenue growth and 82% EBITDA growth in Q1 2026, following the integration of the Prospect acquisition, demonstrate a successful scale-up phase. The shift toward value-based care (80% of care partner revenue in full risk) acts as a margin inflector, as evidenced by the 82% EBITDA growth outpacing revenue growth.

Valuation Context:

• Forward Consensus EPS: FY1 (2026) is $1.27; FY2 (2027) is $1.87.
• Implied Multiple: At a current price of $39.17, the stock trades at approximately 30.8x FY1 EPS and 20.9x FY2 EPS. This valuation reflects high growth expectations and successful integration of the Prospect acquisition.

Conviction Stack:

• Thesis Strength: Low (Tactical only, no macro thesis).
• Evidence Quality: High. Strong earnings beat (56% rev growth, 82% EBITDA growth), clear management guidance, and successful integration of a major acquisition ($674.9M).
• Structural Quality: Moderate/High. The forming coil indicates a base is being built, but the breakout has not fired. The ATR of 3.8% is in the productive range, suggesting the stock is not stagnant but not excessively volatile.
• Setup Readiness: Partial. The setup is "Forming." It is not yet actionable as a confirmed trade.
• Rerating Potential: High, contingent on the successful execution of the FY2026 guidance and the continuation of the margin expansion trend.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Guidance Raise: Management raising the FY2026 revenue or EBITDA range above the current $3.8B–$4.1B and $250M–$280M ranges.
• New Contract Wins: Confirmation of new contracts performing better than the "in line with underwriting" baseline mentioned in Q1.

What Would Invalidate the Case:

• Guidance Miss: A significant miss on the reaffirmed FY2026 outlook (e.g., revenue below $3.8B or EBITDA below $250M).
• Cost Trend Deterioration: Actual cost trends significantly exceeding the 5.2% blended cost trend assumption.

Gaps in Evidence:

• Sector/Industry Classification: The specific sector and industry labels are not provided in the evidence block.
• Cap Bucket: The specific capitalization bucket is not provided.
• Pivot Strength: No specific data on pivot strength is available.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Q1 2026 revenue up 56% YoY to $965.1M and adjusted EBITDA up 82% YoY to $66.3M; Management reaffirmed FY2026 revenue guidance of $3.8B-$4.1B and EBITDA of $250M-$280M; Successful integration of $674.9M Prospect acquisition with cost trends consistent with plan. Key risks: Setup is currently "Forming" and not yet confirmed; High valuation multiple (approx 31x FY1 EPS) leaves little room for guidance misses; Concentration risk with top 4 payers accounting for nearly 60% of net revenue; No named secular thesis to provide tailwind support. Sizing hint: Position size should be conservative given the "Forming" status and lack of confirmed breakout; size based on ATR of 3.8% to manage volatility. Expected path: Price consolidates near current levels while management executes on FY2026 guidance; potential for breakout if earnings momentum continues and technical resistance is cleared. Expected horizon: 3 to 6 months for setup confirmation or invalidation.